Photo from wikipedia
The traditional therapeutic model for patients with metastatic pancreatic cancer is perpetual chemotherapy from diagnosis to death. However, subsets of patients who achieve durable responses to cytotoxic chemotherapy may benefit… Click to show full abstract
The traditional therapeutic model for patients with metastatic pancreatic cancer is perpetual chemotherapy from diagnosis to death. However, subsets of patients who achieve durable responses to cytotoxic chemotherapy may benefit from a switch maintenance approach. Maintenance therapy with the PARP inhibitor olaparib has recently been established for one such subgroup: Patients with germline BRCA mutations. In this talk we will review the available data and the future directions for maintenance therapy including combination treatments and expanding beyond germline BRCA carriers. Citation Format: Kim A Reiss. The end of perpetual chemotherapy? [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2020 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2020;80(22 Suppl):Abstract nr IA-09.
Journal Title: Cancer Research
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!